XCancer

177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia

Description:

To control mCRPC that has spread to the bone marrow. The safety and effects of this treatment will also be studied.

Sponsor:

MD Anderson Cancer Center

Phase:

Phase 2

Contacts:

Bagi Jana, MD

bjana@mdanderson.org

713-563-0670

Government Study Link:

NCT07025512 - Click here to see study on

ClinicalTrials.gov

177Lu-PSMA-617

Isotope(s):
Target(s):
  • PSMA
Ligand Class: Small Molecules
Chelator: DOTA